TABLE 3.

Multivariate regression results postmatching^a

Covariate	Bivariable regression			Multivariable regression
	OR	CI	P value	aOR	CI	P value
Treatment group
Intermittent infusion (reference)
Prolonged infusion	1.21	0.97–1.50	0.093	1.07	0.83–1.39	0.584
Age group
18–44 yr (reference)
45–64 yr	1.21	0.95–1.55	0.12	1.11	0.83–1.48	0.474
65–79 yr	1.19	0.89–1.58	0.25	1.23	0.85–1.78	0.266
≥80 yr	0.80	0.49–1.28	0.376	1.10	0.61–2.00	0.745
Male	1.06	0.86–1.30	0.603
Caucasian	0.78	0.55–1.11	0.15	0.70	0.47–1.03	0.069
Charlson comorbidity score	1.02	1.00–1.05	0.099	1.00	0.97–1.04	0.856
Baseline CLCR of:
30–59 ml/min (reference)
60–89 ml/min	0.86	0.63–1.19	0.362	1.13	0.78–1.65	0.51
≥90 ml/min	1.33	1.02–1.76	0.04	2.42	1.67–3.50	<0.001
Comorbidities
Diabetes	1.09	0.87–1.37	0.454
Heart failure	2.74	2.14–3.50	<0.001	1.78	1.31–2.43	<0.001
ICU admission	1.35	1.08–1.68	0.009	0.99	0.75–1.29	0.918
Hypotension	2.17	1.73–2.72	<0.001	1.43	1.10–1.85	0.007
Hypertension	1.13	0.92–1.38	0.245
β-Lactam
Cefepime (reference)
Meropenem	0.87	0.64–1.19	0.388	1.04	0.73–1.48	0.831
Piperacillin-tazobactam	1.76	1.39–2.22	<0.001	1.95	1.50–2.52	<0.001
Concomitant nephrotoxins
Aminoglycoside	2.41	1.88–3.07	<0.001	1.71	1.29–2.27	<0.001
Amphotericin B	2.84	1.57–5.01	<0.001	2.13	1.03–4.43	0.042
ACE inhibitor	1.23	0.95–1.59	0.103	1.04	0.76–1.41	0.825
ARB	0.94	0.51–1.61	0.828	0.97	0.50–1.88	0.935
i.v. contrast dye	0.79	0.55–1.11	0.193	0.84	0.57–1.24	0.386
Calcineurin inhibitor	2.19	1.40–3.34	<0.001	2.13	1.27–3.57	0.004
Loop diuretic	3.75	3.05–4.64	<0.001	2.74	2.13–3.53	<0.001
NSAIDs	0.80	0.59–1.07	0.137	0.70	0.50–0.99	0.041
Vancomycin	2.39	1.79–3.24	<0.001	1.60	1.16–2.21	0.004
Vasopressor	3.34	2.62–4.24	<0.001	1.98	1.45–2.72	<0.001

^aOR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; CL_CR, creatinine clearance; ICU, intensive care unit; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs.